Tag Archive for: biotech

Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals

/in

Total capital raised across Sofinnova’s platform reaches €1.5Bn over the past year Sofinnova Capital XI is actively investing in early-stage biotech and medtech companies across Europe and the US PARIS, France – November 17, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the close of […]

Read more

Jefferies & London Life Sciences Week 2025

/in

Presented by Optimum Strategic Communications and Catalyst Advisors, this guide is your key to Europe’s biggest week in life sciences. Join global investors, executives, and innovators for a packed schedule of conferences, panels, and networking events. Plan ahead, connect smart, and make every moment count!

Read more

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

/in

AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera’s long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera’s breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund […]

Read more

Women in Life Science Denmark (WiLD) expands mentoring program to support next generation of female leaders in life sciences

/in

Third cohort of cross-organizational, high-level mentorship program to commence in November 2025 Continued support from the Lundbeck Foundation and the Novo Nordisk Foundation WiLD celebrates its third anniversary with 250+ members in Denmark 28 October 2025, Denmark: Women in Life Science Denmark (WiLD) today announces that it is launching the third cohort of its successful […]

Read more

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors

/in

DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression Strasbourg, France – Montreal, Canada – Boston, United States, October 28, 2025: Domain Therapeutics ( “Domain” or “the Company” ), the GPCR experts harnessing deep receptor biology to develop […]

Read more
© Optimum Strategic Communications.